Education
About Us
Working with TipRanks
Follow Us
Circassia Pharmaceuticals PLC (GB:NIOX)
LSE:NIOX
RESEARCH TOOLSreports
NIOX Stock Chart & Stats
Day’s Range― - ―
52-Week Range53.40p - 80.00p
Previous CloseN/A
Volume260.54K
Average Volume (3M)1.27M
Market Cap
£280.04M
Enterprise Value235.23M
Total Cash (Recent Filing)£19.90M
Total Debt (Recent Filing)£1.10M
Price to Earnings (P/E)80.0
Beta0.98
Next Earnings
Sep 11, 2025EPS EstimateN/A
Next Dividend Ex-Date
May 15, 2025Dividend Yield1.42%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding398,343,570
10 Day Avg. Volume788,592
30 Day Avg. Volume1,271,146
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)N/A
Price to Sales (P/S)8.03
Price to Cash Flow (P/CF)26.50
P/FCF Ratio27.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
73.00pPrice Target Upside33.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Circassia Pharmaceuticals News
PremiumCompany Announcements
NIOX Group’s Director-Related Share Transaction Announced
PremiumCompany Announcements
NIOX Group Discontinues Private Sale Amid Economic Challenges
PremiumCompany Announcements
NIOX Group Seeks Block Admission for Share Trading on AIM
PremiumCompany Announcements
NIOX Group Issues New Shares to Executive Directors
PremiumCompany Announcements
Niox Group PLC Sees Increase in Voting Rights by Spreadex LTD---
Bulls Say, Bears Say
Bulls Say
Acquisition InterestNIOX has announced it has received a possible 81p/share all-cash offer from Keensight Capital valuing the business at £322m.
Financial PerformanceNIOX's fiscal year trading update confirms another solid period of growth, with revenues increasing by 14% to £41.8 million, in line with consensus expectations.
Operational EfficiencyStronger-than-expected operational leverage saw adjusted EBITDA grow by 21% to £13.8 million, exceeding consensus estimates.
Bears Say
Acquisition UncertaintyDiscussions are early stages with no formal offer as yet from Keensight.
Valuation ConcernsNIOX trades at a significant discount to peers, with a 2025 estimated price-to-earnings ratio of approximately 13 times, considered too cheap given the company's growth and margin profile.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.79% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.01% Public Companies and
Individual Investors
NIOX FAQ
What was Circassia Pharmaceuticals PLC’s price range in the past 12 months?
Circassia Pharmaceuticals PLC lowest share price was 53.40p and its highest was 80.00p in the past 12 months.
What is Circassia Pharmaceuticals PLC’s market cap?
Circassia Pharmaceuticals PLC’s market cap is £280.04M.
When is Circassia Pharmaceuticals PLC’s upcoming earnings report date?
Circassia Pharmaceuticals PLC’s upcoming earnings report date is Sep 11, 2025 which is in 151 days.
How were Circassia Pharmaceuticals PLC’s earnings last quarter?
Circassia Pharmaceuticals PLC released its earnings results on Apr 01, 2025. The company reported -0.002p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002p.
Is Circassia Pharmaceuticals PLC overvalued?
According to Wall Street analysts Circassia Pharmaceuticals PLC’s price is currently Undervalued.
Does Circassia Pharmaceuticals PLC pay dividends?
Circassia Pharmaceuticals PLC pays a Annually dividend of 1.25p which represents an annual dividend yield of 1.42%. See more information on Circassia Pharmaceuticals PLC dividends here
What is Circassia Pharmaceuticals PLC’s EPS estimate?
Circassia Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Circassia Pharmaceuticals PLC have?
Circassia Pharmaceuticals PLC has 398,343,570 shares outstanding.
What happened to Circassia Pharmaceuticals PLC’s price movement after its last earnings report?
Circassia Pharmaceuticals PLC reported an EPS of -0.002p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.789%.
Which hedge fund is a major shareholder of Circassia Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:NIOX
---
Circassia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
73.00p (33.70% Upside)
73.00p (33.70% Upside)
Insider Transactions
Bought Shares
Worth £25.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.09%
12-Months-Change
Fundamentals
Return on Equity
4.55%
Trailing 12-Months
Asset Growth
-25.25%
Trailing 12-Months
Company Description
Circassia Pharmaceuticals PLC
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
---
NIOX Stock 12 Month Forecast
Average Price Target
73.00p
▲(33.70% Upside)
Technical Analysis
Best Analysts Covering NIOX
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-15.84%
reiterated a buy rating 3 days ago
Copying James Orsborne's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.84% per trade.
---